Semantic Scholar uses AI to extract papers important to this topic.
The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive breast cancer has led to dramatic… Expand Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers… Expand Targeted drug delivery has improved cancer treatment significantly in recent years, although it is difficult to achieve… Expand 1014Background: SYD985, (vic-)trastuzumab duocarmazine, is a HER2-targeting antibody-drug conjugate with a cleavable linker… Expand BACKGROUND
Epithelial ovarian cancer (EOC) is an aggressive and heterogeneous disease. <10% of EOC demonstrate HER2/neu 3… Expand Purpose: Carcinosarcomas (CS) are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous… Expand Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer. Up to 35% of USC may overexpress the HER2/neu… Expand Antibody-drug conjugates (ADCs) that are currently on the market or in clinical trials are predominantly based on two drug… Expand SYD985 is a HER2-targeting antibody–drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin… Expand A linker-drug platform was built on the basis of a cleavable linker-duocarmycin payload for the development of new-generation… Expand